| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| License revenue-License | -70,006 | 70,000 | NaN |
| Segment research and development expense | -161,800 | 81,105 | NaN |
| Segment general and administrative expense | NaN | 18,118 | NaN |
| Segment selling, general and administrative expense | 31,055 | NaN | NaN |
| Share-based compensation expense (see note 10) | -18,924 | 11,250 | NaN |
| Total operating expenses | 116,189 | NaN | NaN |
| Other items | 7,483 | -5,874 | NaN |
| Net loss | 117,345 | -34,599 | -187,647 |
| Non-cash lease expense | NaN | -13 | -17 |
| Share-based compensation expense | -18,924 | 11,250 | 21,064 |
| Non-cash interest expense | 2,036 | 308 | NaN |
| Depreciation and amortization | -219 | 110 | 230 |
| Non-cash interest expense and amortization of debt issuance costs | NaN | NaN | 206 |
| Accretion and amortization of available-for-sale securities | -3,148 | 1,133 | 3,872 |
| Deferred revenue - related party | NaN | NaN | -144 |
| Net loss on disposal of equipment | NaN | 0 | NaN |
| Change in fair value of derivative liability | 7,530 | NaN | NaN |
| Unbilled revenue | NaN | 70,000 | 0 |
| Other non-cash items | -169 | NaN | NaN |
| Prepaid expenses and other assets | 11,183 | -3,370 | -5,479 |
| Accounts payable | -3,312 | 1,546 | 6,396 |
| Accrued and other liabilities | -18,577 | 4,612 | -9,721 |
| Net cash used in operating activities | 132,983 | -84,611 | -168,026 |
| Purchases of marketable securities | -49,764 | 14,086 | 126,998 |
| Maturities of marketable securities | -274,592 | 140,290 | 302,906 |
| Purchase of property and equipment | -232 | 127 | 128 |
| Net cash provided by investing activities | -224,596 | 126,077 | 175,780 |
| Proceeds from the issuance of common stock-September2022ATMAgreement | NaN | NaN | 4,944 |
| Proceeds from sale of common stock in public offering | NaN | 0 | NaN |
| Proceeds from the issuance of common stock-January2024Public Offering | NaN | NaN | 0 |
| Proceeds from sale of common stock in at-the-market offerings | -14,904 | 14,904 | NaN |
| Payments of issuance costs associated with sale of common stock-Common Stock | NaN | 209 | 207 |
| Proceeds from the issuance of series b preferred stock, pursuant to september 2024 public offering | NaN | 0 | NaN |
| Payments of issuance costs associated with sale of common stock-Preferred Stock | NaN | 0 | NaN |
| Payments of issuance costs associated with the sale of common stock | 0 | NaN | NaN |
| Proceeds from the exercise of warrants | -1,618 | 0 | 1,618 |
| Proceeds from issuance of common stock upon exercises of stock options | 2,750 | 547 | 3,060 |
| Proceeds from issuance of common stock under employee stock purchase plan | -1,120 | 559 | 561 |
| Net cash provided by financing activities | -14,476 | 10,857 | 9,976 |
| Net increase (decrease) in cash and cash equivalents | -106,089 | 52,323 | 17,730 |
| Cash and cash equivalents at beginning of period | 169,647 | 99,594 | NaN |
| Cash and cash equivalents at end of period | 176,346 | 169,647 | NaN |
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)